- Secures first regulatory approval for Lavieen in Mexico following its successful performance in Brazil, establishing two key footholds in the Latin American market
- Receives recognition from Mexican health authorities for Lavieen’s effectiveness in soft tissue coagulation procedures and treatment of benign pigmented lesions
- Plans to strengthen local partnerships, pursue additional product approvals, and support medical professionals to drive continued growth across the Latin American market
(February 3, 2026) WONTECH Co., Ltd. (KOSDAQ: 336570), a laser and energy-based medical solutions company led by CEOs Kim Jong-won and Kim Jung-hyun, has obtained regulatory approval from Mexico’s health authority, COFEPRIS, for its laser device Lavieen. Following Brazil, the company has now secured entry into Mexico, establishing a presence in the two largest markets in Latin America.
Mexico’s health authority approved Lavieen as a dermatological medical device. Based on a 1927 nm Thulium laser, the system is recognized for its effectiveness in soft tissue coagulation procedures as well as the treatment of benign pigmented lesions, including actinic keratosis, lentigines, solar lentigines, and freckles. Lavieen enables precise treatment from the epidermis to the dermal layer, offering the advantages of rapid recovery and minimal downtime.
Building on the stable performance achieved in Brazil, the largest market in South America, WONTECH has now secured approval in Mexico, establishing a strategic foundation that connects two key hubs in the Latin American market. In Brazil alone, Lavieen recorded a major milestone with cumulative exports of 1,200 units by 2025, solidifying its position as a game changer in the regional market. Leveraging the proven technology and product competitiveness demonstrated in Brazil, WONTECH plans to expand what it describes as the “Brazil success formula” across the broader Latin American region.
The medical aesthetics market in Latin America continues to grow steadily, driven by rising income levels, the mainstream adoption of aesthetic and dermatological procedures, and increasing demand for non-invasive and minimally invasive laser treatments. In particular, demand for clinically proven laser devices is expanding in areas such as pigmented lesion treatment, skin regeneration, and anti-aging. WONTECH plans to accelerate its expansion across the region by securing early leadership in high-growth markets, particularly Brazil and Mexico—the two largest markets in Latin America.
A WONTECH official stated, “With Brazil and Mexico secured as the two key markets in Latin America, we will accelerate our phased expansion into other major countries across the region.” The official added, “We will continue to strengthen local partnerships, pursue additional product approvals, and expand physician education programs and clinical support while growing together with local medical institutions.”
Meanwhile, WONTECH continues to expand its global presence, with more than 60% of its total revenue generated from overseas markets. The company has secured major international regulatory approvals, including U.S. FDA, European CE, Brazil ANVISA, and Thailand FDA, and currently supplies its products to more than 80 countries through local subsidiaries in the United States, Japan, and Thailand.
- Receives recognition from Mexican health authorities for Lavieen’s effectiveness in soft tissue coagulation procedures and treatment of benign pigmented lesions
- Plans to strengthen local partnerships, pursue additional product approvals, and support medical professionals to drive continued growth across the Latin American market
▲ Lavieen Product Image
(February 3, 2026) WONTECH Co., Ltd. (KOSDAQ: 336570), a laser and energy-based medical solutions company led by CEOs Kim Jong-won and Kim Jung-hyun, has obtained regulatory approval from Mexico’s health authority, COFEPRIS, for its laser device Lavieen. Following Brazil, the company has now secured entry into Mexico, establishing a presence in the two largest markets in Latin America.
Mexico’s health authority approved Lavieen as a dermatological medical device. Based on a 1927 nm Thulium laser, the system is recognized for its effectiveness in soft tissue coagulation procedures as well as the treatment of benign pigmented lesions, including actinic keratosis, lentigines, solar lentigines, and freckles. Lavieen enables precise treatment from the epidermis to the dermal layer, offering the advantages of rapid recovery and minimal downtime.
Building on the stable performance achieved in Brazil, the largest market in South America, WONTECH has now secured approval in Mexico, establishing a strategic foundation that connects two key hubs in the Latin American market. In Brazil alone, Lavieen recorded a major milestone with cumulative exports of 1,200 units by 2025, solidifying its position as a game changer in the regional market. Leveraging the proven technology and product competitiveness demonstrated in Brazil, WONTECH plans to expand what it describes as the “Brazil success formula” across the broader Latin American region.
The medical aesthetics market in Latin America continues to grow steadily, driven by rising income levels, the mainstream adoption of aesthetic and dermatological procedures, and increasing demand for non-invasive and minimally invasive laser treatments. In particular, demand for clinically proven laser devices is expanding in areas such as pigmented lesion treatment, skin regeneration, and anti-aging. WONTECH plans to accelerate its expansion across the region by securing early leadership in high-growth markets, particularly Brazil and Mexico—the two largest markets in Latin America.
A WONTECH official stated, “With Brazil and Mexico secured as the two key markets in Latin America, we will accelerate our phased expansion into other major countries across the region.” The official added, “We will continue to strengthen local partnerships, pursue additional product approvals, and expand physician education programs and clinical support while growing together with local medical institutions.”
Meanwhile, WONTECH continues to expand its global presence, with more than 60% of its total revenue generated from overseas markets. The company has secured major international regulatory approvals, including U.S. FDA, European CE, Brazil ANVISA, and Thailand FDA, and currently supplies its products to more than 80 countries through local subsidiaries in the United States, Japan, and Thailand.